Cargando…
Continued Discontinuation of TKI Treatment in Medullary Thyroid Carcinoma – Lessons From Individual Cases With Long-Term Follow-Up
BACKGROUND: The tyrosine kinase inhibitors (TKI) vandetanib and cabozantinib are approved as targeted therapies in advanced medullary thyroid carcinoma (MTC) with symptoms or high tumour burden. Only recently, toxicity in long-time TKI usage was analysed. However, little is known about the impact of...
Autores principales: | Brandenburg, Tim, Tiedje, Vera, Muchalla, Philipp, Theurer, Sarah, Weber, Frank, Schmid, Kurt Werner, Dralle, Henning, Führer, Dagmar |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8511790/ https://www.ncbi.nlm.nih.gov/pubmed/34659114 http://dx.doi.org/10.3389/fendo.2021.718418 |
Ejemplares similares
-
DLL3 (delta-like protein 3) expression correlates with stromal desmoplasia and lymph node metastases in medullary thyroid carcinomas
por: Ingenwerth, M, et al.
Publicado: (2021) -
Predictive Factors for RAI-Refractory Disease and Short Overall Survival in PDTC
por: Kersting, David, et al.
Publicado: (2021) -
Enhancing Radioiodine Incorporation into Radioiodine-Refractory Thyroid Cancer with MAPK Inhibition (ERRITI): A Single-Center Prospective Two-Arm Study
por: Weber, Manuel, et al.
Publicado: (2022) -
Paraganglioma-induced Catecholamine-mediated Gangrene
por: Brandenburg, Tim, et al.
Publicado: (2022) -
Analysis of risk factors and prognosis in differentiated thyroid cancer with focus on minimal extrathyroidal extension
por: Weber, Manuel, et al.
Publicado: (2021)